Agencies rock for a good cause at Pharmapalooza

Share this article:
Agencies rock for a good cause at Pharmapalooza
Agencies rock for a good cause at Pharmapalooza

Corbett Accel Healthcare Group can add music to its list of creative achievements after its Chicago office triumphed in last night's Pharmapalooza “battle of the bands” contest at B.B. King's Blues Club & Grill in New York City.

Heavy Medical — comprising Jeff Holtorf (drums), Terry Barich (harmonica, vocals), Brian Catral (keyboards, vocals), Jack Cunningham (bass, vocals), Joe Mason (theremin, vocals), Matt Pearl (guitar, vocals) Nicole Stachura (percussion, vocals) and Kelly Christiansen (percussion, vocals) — rocked a sell-out crowd of 750 vociferous industry colleagues and supporters.

In second place was Late Night Car Service (a.k.a. Sudler & Hennessey) which got the vote from MM&M's unofficial panel in attendance. But the real winners of the charity event, which was conceived and organized by New York-based Cline Davis & Mann, was the Children's Hospital at Montefiore, for whom more than $110,000 was raised.

Other contestants were May Cause Nausea (Ogilvy Healthworld), Grand pRx (GSW Worldwide), Pharmatopia (Corbett Accel New York), Mr. Tiny's Revenge (Grey Healthcare Group), SIDEFX (Regan Campbell Ward • McCann), BANDRx (AgencyRx) and Black Box Warning (Harrison & Star). CDM had set the tone with an impressive opening set from its 21-member ensemble, Uncle Funkus.

 

Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.